Shanghai Fudan Zhangjiang Bio Pharmaceutical Co (HK:1349) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.’s subsidiary has received acceptance from China’s National Medical Products Administration for its new drug application of Obeticholic Acid Tablets, targeting primary biliary cholangitis. This development taps into the significant market potential in China, a nation with a high incidence of hepatobiliary diseases. The acceptance marks a key milestone in the company’s strategy to strengthen its product line and competitive edge in the pharmaceutical market.
For further insights into HK:1349 stock, check out TipRanks’ Stock Analysis page.
